ATC Group: M04A Antigout preparations

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M04A in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M04 Antigout preparations
3 M04A Antigout preparations

Group M04A contents

Code Title
M04AA Preparations inhibiting uric acid production
M04AB Preparations increasing uric acid excretion
M04AC Preparations with no effect on uric acid metabolism
M04AX Other antigout preparations

Active ingredients in M04A

Active Ingredient Description
Allopurinol

Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid.

Benzbromarone
Colchicine

Colchicine is considered to act against the inflammatory response to urate crystals, by possibly inhibiting the migration of granulocytes into the inflamed area. Other properties of colchicine, such as interaction with the microtubules, could also contribute to the operation. Onset of action is approximately 12 hours after oral administration and is maximal after 1 to 2 days.

Febuxostat

Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.

Lesinurad

Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric acid (sUA). Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced hyperuricaemia.

Pegloticase

Pegloticase is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water soluble purine metabolite; it is readily eliminated, primarily by renal excretion.

Probenecid

Probenecid is a uricosuric and renal tubular blocking agent. It inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits.

Topiroxostat

Related product monographs

Title Information Source Document Type  
ADENURIC Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
COLCHICINA Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
COLCHICINE Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
KRYSTEXXA Solution for infusion FDA, National Drug Code (US) MPI, US: SPL/PLR
PROBENECID-AFT Film coated tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
ULORIC Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
ZYLOPRIM Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
ZYLORIC Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC